PT  - JOURNAL ARTICLE
AU  - Simon R. Mucha
AU  - Siddharth Dugar
AU  - Keith McCrae
AU  - Douglas Joseph
AU  - John Bartholomew
AU  - Gretchen L. Sacha
AU  - Michael Militello
TI  - Update to coagulopathy in COVID-19: Manifestations and management
AID  - 10.3949/ccjm.87a.ccc024-up
DP  - 2020 Dec 15
TA  - Cleveland Clinic Journal of Medicine
4099  - http://www.ccjm.org/content/early/2020/12/14/ccjm.87a.ccc024-up.short
4100  - http://www.ccjm.org/content/early/2020/12/14/ccjm.87a.ccc024-up.full
AB  - Severe COVID-19 illness is associated with intense inflammation, leading to high rates of thrombotic complications that increase morbidity and mortality. Markedly elevated levels of D-dimer with normal fibrinogen levels are the hallmark laboratory findings of severe COVID-19–associated coagulopathy. Prophylaxis against venous thromboembolism is paramount for all hospitalized patients with COVID-19, with more aggressive prophylaxis and screening recommended for critically ill patients with D-dimer levels above 3.0 μg/mL. Point-of-care ultrasonography is the imaging method of choice for patients at high risk, as it entails minimal risk of exposing providers to the virus.